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Failed superficial femoral artery intervention for
advanced infrainguinal occlusive disease has a
significant negative impact on limb salvage
Omar Al-Nouri, DO,a Monika Krezalek, BS,a Richard Hershberger, MD,b Pegge Halandras, MD,b
Andrew Gassman, MD,a Bernadette Aulivola, MD,b and Ross Milner, MD,b Maywood, Ill
Objective: Endovascular treatment of superficial femoral artery (SFA) lesions is a well-established practice. The repercus-
sions of failed SFA interventions are unclear. Our goal was to review the efficacy of SFA stenting and define negative
effects of its failure.
Methods: A retrospective chart review was conducted from January 2007 to January 2010 that identified 42 limbs in 39
patients that underwent SFA stenting. Follow-up ankle-brachial index and a duplex ultrasound scan was performed at
routine intervals.
Results:Mean patient age was 68 years (range, 43-88 years); there were 22 men (56%) and 17 women (44%). Intervention
indication was claudication in 15 patients (36%), rest pain in seven patients (17%), and tissue loss in 19 patients (45%).
There were 15 patients (36%) with TransAtlantic Inter-Society Consensus (TASC) A, nine patients (21%) with TASC B,
five patients (12%) with TASC C, and 13 patients (31%) with TASCD lesions. The majority of lesions intervened on were
the first attempt at revascularization. Three stents (7.7%) occluded within 30 days. One-year primary, primary-assisted,
and secondary patency rates were 24%, 44%, and 51%, respectively. Limb salvage was 93% during follow-up. Seventeen
interventions failed (40%) at 1 year. Of these, seven patients (41%) developed claudication, seven patients (41%) developed
ischemic rest pain, and three patients (18%) were asymptomatic. During follow-up, three patients (7.7%) required bypass and
three patients (7.7%) major amputation, one after failed bypass. All limbs requiring bypass or amputation had TASC C/D
lesions. Thirty-day and 1-year mortality was 2.6% and 10.3%, respectively.
Conclusions: Interventions performed for TASC C/D lesions are more likely to fail and more likely to lead to bypass or
amputation. Interventions performed for TASCC/D lesions that fail have a negative impact on limb salvage. This should
be considered when performing stenting of advanced SFA lesions. ( J Vasc Surg 2012;56:106-12.)
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mThemost advanced form of lower extremity atheroscle-
rotic disease, critical limb ischemia (CLI), has significant
morbidity and mortality for many aging Americans. CLI,
defined as chronic ischemic rest pain, ulcers, or gangrene,
has challenged vascular specialists for decades.1
Traditionally, the mainstay treatment strategy for limb
revascularization in this patient population has been open
surgical bypass. However, since the advent of balloon an-
gioplasty 30 years ago,2 there has been a large increase in
endovascular treatment (balloon angioplasty and stenting)
of lower extremity atherosclerotic disease.
In the article by Goodney et al,3 they have shown that
in the past decade, there has been a threefold increase in
endovascular treatment of lower extremity atherosclerotic
disease with a simultaneous 42% decrease in open surgical
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106ypass. The TransAtlantic Inter-Societal Consensus
TASC) reported recommendations both in 2000 and
007. Lesions defined as TASC A should undergo endo-
ascular treatment as the first-line therapy, whereas le-
ions defined as TASC D should undergo traditional open
urgical bypass. It was unclear what the ideal treatment strat-
gy is for TASC B and C lesions, but the consensus was that
ost TASCB lesions underwent endovascular treatment, and
ost TASC C lesions underwent open surgical bypass.4
With the increasing number of endovascular proce-
ures being performed, many authors recommend an ag-
ressive endovascular approach to the treatment of ad-
anced infrainguinal lesions (TASC C/D). Multiple
tudies5,6 have shown acceptable patency rates for endovas-
ular treatment of advanced infrainguinal lesions with min-
mal periprocedural complications.
Opponents to endovascular treatment of these advanced
esions argue that the effects of a failed infrainguinal interven-
ion can negatively impact further revascularization and limb
alvage.7 However, a paucity of data exist defining the nega-
ive effects of a failed infrainguinal intervention. The purpose
f this study was to determine the negative effects of a failed
uperficial femoral artery (SFA) intervention.
ETHODS
After institutional review board approval, the electronic
edical records of all patients undergoing angioplasty and
tenting of the superficial femoral and popliteal arteries at a
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Volume 56, Number 1 Al-Nouri et al 107single institution during a 36-month period were reviewed.
Using Current Procedure Terminology (CPT) codes
37205, 75962, and 35474, patients were selected that
underwent stenting of SFA lesions alone. Stent placement
occurred when a residual stenosis (ie, 30%) was found
after balloon angioplasty or when a lesion was determined
on angiogram to not be amenable to balloon angioplasty
alone. No stents were primarily placed after a complication
of balloon angioplasty (ie, dissection). Patients undergoing
angioplasty alone or angioplasty or stenting of concomitant
popliteal or tibial lesions were excluded. Only patients
undergoing stenting of the SFAwere included in this study.
Interventions were performed or supervised by five
vascular surgeons. SFA lesions were classified according to
the second TASC II classification and determined by the
treating surgeon. Patient gender, demographics, presence
of comorbidities, body mass index, history of end-stage
renal disease, history of smoking, and use of anticoagula-
tion therapy were recorded. Indications for intervention,
location, length, severity of arterial lesions, type and size of
stent deployed, and quality of distal runoff were noted.
Runoff at the tibial level was determined by the number of
vessels patent (zero, one, two, or three). Distal vessel runoff
was determined by angiographic evaluation and evaluation
of dictated operative reports. Complications including ac-
cess site hematoma, clinical myocardial infarction, amputa-
tions, and death were recorded.
Type and number of secondary interventions were
noted. The type of stent was chosen on the basis of surgeon
preference (Table I). All patients received a bolus of 150 to
300 mg of clopidogrel postintervention and were main-
tained on 75 mg of clopidogrel for at least 30 days postin-
tervention. All patients were systemically heparinized with
80 units/kg of heparin before angioplasty and stenting.
Activated clotting time levels were not routinely checked.
Initial procedural success occurred when the treated arterial
segment had 30% stenosis remaining.
Patients received duplex scans and arterial-brachial in-
dices every 3 months for the first year. Loss of primary
patency was considered to have occurred with vessel occlu-
sion or when a hemodynamically significant stenosis was
detected on duplex scanning. We considered a 50% stenosis
to be present when a peak systolic velocity was greater than
200 and a 2:1 velocity ratio was seen across the lesion.
SFA interventions requiring repeat angioplasty or
Table I. Stent types with use of frequency
Stent type
Number of
patients
(n 
74) (%)
Atrium ICAST stent 2 (2.7)
Cordis SMART stent 62 (83.7)
Edwards Life Science Lifestent 4 (5.4)
Atrium ICAST stent 6 (8.1)stenting of previously occluded or stenotic SFA stents to raintain patency were recorded. Stent occlusions requiring
tent thrombectomy were also noted and considered to be
econdarily patent. Stent thrombectomy was accomplished
y performing percutaneous mechanical thrombectomy
ith use of an initial pulse-spray technique and use of the
ngiojet DVX catheter system (Medrad, Inc, Pittsburgh,
a). After thrombectomy, tissue plasminogen activator in-
usion was continued for 24 hours, or a subsequent balloon
ngioplasty with possible stent placement was performed
or residual stenosis (30%). Primary, primary-assisted,
nd secondary patency rates were recorded throughout the
uration of the study period and used as outcomemeasures
hen plotting survival curves.
ESULTS
Between January 2007 and January 2010, 500 diag-
ostic angiograms and balloon angioplasties were per-
ormed. Forty-two endovascular stenting procedures of
FA lesions were performed in 39 patients. Nine patients,
ith nine compromising stents, were lost to follow-up at 1
ear but were included in the study. Twenty-two patients
ere men (56%) and 17 were women (44%). Mean patient
ge was 68 years (range, 43-88 years). Patient’s comorbidi-
ies are listed in Table II. Of the 42 stents placed, 19 (45%)
ere placed for tissue loss, 15 (36%) for claudication, and
even (17%) for rest pain. Technical success rate was 100%.
t 1-year, follow-up was available for 34 limbs with a mean
f 14.9 months (range, 1-42 months).
Superficial femoral arterial segments treated were the
nly lesions included in this study. Thirty-two of 42
imbs had “good” (ie, two distal vessels) distal vessel
unoff scores. Fifteen lesions were classified as TASC A
36%), nine were TASC B (21%), five were TASC C
12%), and 13 were TASC D (31%).
Overall primary patency, primary-assisted, and second-
ry patency rates at 1 year were 24%, 44%, and 51%,
espectively (Fig 1). Primary, primary-assisted, and second-
ry patency rates at 1 year for TASC A lesions were 47%,
6%, and 72%, respectively; for TASC B, 13%, 33%, and
3%, respectively; for TASC C, 40%, 40%, and 40%, respec-
ively; and for TASCD, 0%, 32%, and 46%, respectively (Fig
). When stratifying for patients who have had at least
-year follow-up and more, primary, primary-assisted, and
econdary patency rates increase to 34%, 54%, and 63%,
able II. Patient comorbidities and risk factors
isk factors
Number of patients
(n  39) Percentage
oronary artery disease 19 49
yocardial infarction 9 23
ypertension 36 92
iabetes 19 49
ypercholesterolemia 29 74
nd-stage renal disease 6 15
arfarin anticoagulation 5 11
moking history 30 77espectively. Limb salvage was 93% during follow-up. SE
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July 2012108 Al-Nouri et alfor calculated Kaplan-Meier patency curves was 10% at
12-month follow-up. In univariate analysis, history of hy-
percholesterolemia and smoking had a negative impact on
primary patency (Table III).
Seventeen interventions failed (40%) at 1 year. Of the
17 failed interventions, nine stent failures were due to
significant stenosis and eight were due to occlusions. Of the
nine stent failures due to stenosis, six were due to intrastent
stenosis and three were due to native arterial stenosis. SFA
failure was evenly distributed among TASC classifications,
with five classified as TASC A, four as TASC B, three as
TASC C, and five as TASC D. Of the 17 failed SFA
interventions, at the time of stent failure, symptoms were
the following: seven (41%) had claudication, seven (41%)
Fig 1. A, Overall 1-year primary patency. B, Overall 1-year pri-
mary-assisted patency.had ischemic rest pain, and three (18%) remained asymp- tomatic. Of the seven failed SFA interventions, only one
rogressed from claudication symptoms preprocedure to
eveloping ischemic rest pain after stent failure. Thirty-day
nd 1-year mortality was 2.6% and 10.3%, respectively.
During follow-up, of the 17 failed SFA interventions,
hree went on to open bypass for limb salvage and three
ent on to major amputation (one after a failed bypass).
he six limbs requiring either bypass or major amputation
ere TASC C or D lesions (Table IV). Of the patients that
equired amputation, one patient underwent stenting for
hronic total occlusion of the SFA with tissue loss. Patency
as lost and multiple percutaneous reinterventions failed.
n open bypass was performed that failed and the patient
nderwent a below-the-knee amputation (BKA). The sec-
nd patient underwent bilateral SFA stenting for gangrene.
atency of both stents was lost within 30 days and the
atient subsequently underwent bilateral amputation for
evere wet gangrene.
Of the patients requiring open bypass for limb salvage,
ne patient underwent stenting for chronic total occlusion
f SFA with rest pain, primary patency was lost within 30
ays, subsequent graft thrombolysis failed, and the patient
nderwent open bypass for CLI. A second patient under-
ent SFA stenting for nonhealing burn wounds that
ailed within 3 days without an attempt at revasculariza-
ig 2. One-year primary patency by TransAtlantic Inter-Society
onsensus (TASC) classification.
able III. Risk factors: univariate analysis
ariable
Hazard ratio
(95% confidence
interval) P value
ypercholesterolemia 4.5 (0.851-24.00) .077
moking history 6.088 (1.001-37.028) .050
iabetes 3.012 (0.681-13.329) .146
ypertension 0.287 (0.020-4.048) .355ion. This patient underwent open bypass in order to
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Volume 56, Number 1 Al-Nouri et al 109heal his wounds. A third patient with a previous iliofem-
oral bypass underwent SFA stenting for persistent foot
ulceration. Patency was lost and, after multiple failed
percutaneous reinterventions, open bypass was per-
formed for CLI.
Distal vessel runoff was only affected in two failed SFA
interventions. This change did not alter the bypass options
for one patient. However, in the second patient, the bypass
performed for CLI subsequently failed and the patient
underwent a BKA.
Based on this experience, it seems that interventions
performed for TASC C and D lesions are more likely to fail
and more likely to lead to bypass for limb salvage or
amputation, and, therefore, have a negative impact on limb
salvage.
DISCUSSION
Peripheral arterial disease, which affects 8 to 10 million
Americans in the United States, continues to contribute a
significant morbidity andmortality to patients with vascular
problems.8 Progression of disease from stable claudication
to CLI may occur and necessitates a comprehensive care
plan for these patients. Treatment strategies range from
medical therapy with risk factor reduction to endovascular
therapy to open surgical bypass. Recent advances in endo-
vascular technology and skill has sparked interest in endo-
vascular treatment of advanced infrainguinal occlusive dis-
ease.9 With improvement in nitinol stents and utilization of
the subintimal technique, many authors advocate endovas-
cular treatment of many advanced TASC D type femoro-
popliteal lesions.5 Reported 1- and 2-year patency rates
rival those for open surgical bypass. Baril et al,5 in their
review of 79 TASC D limbs treated with endovascular
stenting, showed 1-year primary and primary-assisted pa-
tency rates of 52.5% and 88.4%, respectively.
Few randomized prospective trials exist comparing the
efficacy of endovascular treatment with stenting vs open
surgical bypass for SFA lesions. McQuade et al10 reported
long-term primary patency rates of endovascular-treated
lesions similar to those of surgical bypass-treated lesions. In
their study, primary patency in the stent graft group was
72%, 63%, 63%, and 59% at 12, 24, 36, and 48 months,
respectively, compared to the surgical bypass group with
12, 24, 36, and 48 months of primary patency rates of 76%,
63%, 63%, and 58%, respectively. However, these studies
fail to look at the affect of a failed SFA intervention on limb
Table IV. Outcomes of failed SFA intervention by TASC
Event
TASC A
(n  15)
Stent failure 5
Loss of runoff vessels 0
Open revascularization 0
Major amputation 0
SFA, Superficial femoral artery; TASC, TransAtlantic Inter-Society Consenssalvage. aA recent retrospective review by Gur et al7 examined
heir 5-year experience with endovascular treatment of SFA
esions. In their report, they found that lesions classified as
ASC C or D were more likely to fail with occlusion, lose
unoff vessels, and can alter the site of subsequent open
peration than their TASC A or B counterparts. The au-
hors concluded that a failed SFA intervention in advanced
nfrainguinal occlusive disease may negatively impact later
ttempts at revascularization.
In our study, SFA stenting performed for TASCC or D
esions was more likely to fail and more likely to lead to
ypass or amputation when compared to TASC A or B
esions. When an SFA intervention failed with stent occlu-
ion in TASC C or D lesions, they were more likely to
ndergo major amputation. None of the patients in our
tudy that had TASC A or B lesions that had loss of patency
equired any further intervention. Patients that were inter-
ened for claudication, despite having a hemodynamically
ignificant stenosis or occlusion, were more likely to either
e asymptomatic or have tolerable claudication and not
equire a bypass or amputation, whereas patients inter-
ened for CLI that had a failed SFA intervention were more
ikely to lead to multiple attempts at open revascularization
nd major amputation.
The higher amputation rate seen in our study in more
dvanced TASC C/D lesions compared to TASC A/B
esions may just represent the extent of disease. Several
uthors7,11 have found that failed SFA interventions in
dvanced TASC C/D lesions effect subsequent distal by-
ass procedures. When performing endovascular stenting
f advanced TASC C/D lesions with use of angioplasty in
he subintimal plane, loss of collateral circulation can occur.
ithout this circulation in place, if stent failure occurs,
atients may progress to more advanced clinical disease.
urthermore, with the lack of collateral circulation in place,
here is a theoretic risk of stent thrombosis propagating to
unoff vessels and effecting limb salvage.
In our series, six patients with failed SFA interventions
ent on to undergo major amputation or bypass. Four
atients required open surgical bypass; one of them failed
nd required a BKA. Of the three remaining bypasses, two
f them required further secondary balloon angioplasty for
nastomotic stenosis and one of them required an open
urgical revision. None of the amputations occurred in the
ace of patent stents. Overall limb salvage was 93%. None of
ur patients with a failed SFA intervention crossed over to
ification
TASC B
(n  9)
TASC C
(n  5)
TASC D
(n  13)
4 3 5
0 0 2
0 1 2
0 2 1classmore advanced TASC classification. Only one patient
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stenting for claudication that failed progressed to rest pain
with no tissue loss. This patient refused any further inter-
vention. Similar to findings in the bypass vs angioplasty in
severe ischemia of the leg (BASIL) trial,11 four of the six
failed SFA interventions had significant negative impact on
patency of bypass grafts and limb salvage. It seems that the
stenting first with no consequence adage can be detrimen-
tal to both limb salvage and to further attempts at revascu-
larization.
We conclude that patients with advanced infrainguinal
occlusive disease with CLI (TASC C/D lesions) would
likely benefit from open surgical bypass over endovascular
stenting. However, many of these patients are not appro-
priate surgical candidates and endovascular therapy is the
only option. These patients present a difficult treatment
dilemma for vascular surgeons. Based on our study, patients
with CLI that undergo a failed percutaneous SFA interven-
tion have a higher likelihood of amputation. Furthermore,
stent thrombosis may have a negative impact on bypass
patency. The higher amputation rates seen in patients with
TASC C or D lesions compared to TASC A or B lesions
again may just represent extension of disease. Randomized
control trials comparing stenting vs open bypass in ad-
vanced TASC C and D lesions with limb salvage as the
primary outcome would shed some light on the subject.
Patients with advanced TASC C or D lesions that undergo
stenting for claudication are more likely to fail than their
TASC A or B counterparts, but a failed SFA intervention in
these patients does not necessarily lead to amputation or
bypass. Based on this experience, patients with lifestyle-
limiting claudication with TASC C and D lesions that are
appropriate surgical candidates and have adequate autoge-
nous vein available should undergo open surgical bypass as
opposed to endovascular therapy.
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Dr Peter Rossi (Milwaukee, Wisc). Thank you, Dr Al-Nouri,
for the nice presentation. I would like to thank the program
committee for giving me the opportunity to review this and
thank Dr Al-Nouri for getting me the article several weeks ago.
The article is a nice summary of isolated superficial femoral
artery stenting for infrainguinal disease, and, despite the small
number of patients in the series and the small number of limbs,
I think it does give us some valuable insights. The 93% overall
limb salvage rate in your article is laudable. It is interesting,
though, that 31% of the cases that were done here were for
TASC D lesions and 36% overall were done for claudication.
When I examined the data and just sat down with a calculator, if
I eliminated the claudication patients, the actual limb salvageedo infrainguinal bypass procedures. I’m a little bit curious.
ould you comment on that? I have four overall questions
egarding your manuscript. One, in your results in the manu-
cript, you mentioned that there were “500 lower extremity
ngioplasty and diagnostic angiogram procedures,” so if I take it
hat you stented 42 of these, that gives you a 92% rate of isolated
ercutaneous transluminal angioplasty and you only stented
bout 8%. I’m wondering what your criteria were for actually
lacing stents and whether the fact that you stented a lesion
eant that it was a higher-risk lesion and perhaps more likely to
ail. Our group has previously shown that the number of patent
unoff vessels is directly proportional to the rate of success of
hese procedures. You mentioned in your manuscript that you
ad an average of 2.1 patent tibial vessels in your procedures
ere, and I’m wondering if you examined the patency of the
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Volume 56, Number 1 Bush 111runoff in terms of the success of the intervention. The third
question is about your medical management. You did mention
that the patients were on aspirin and Plavix, or one of the two.
I’m curious as to whether you put these patients on statins or
how involved you get in the medical management. There are
certainly data that suggest improved patency and better out-
comes with patients who are on statins and angiotensin-converting
enzyme (ACE) inhibitors. I don’t know if you’re involved with
that. Probably my only concern with the manuscript is that you do
make the statement that the failure of these procedures for TASC
C and D lesions leads to a decrease in limb salvage, and I’m not
really sure that you showed that. The reason I say that is that they
are moving on to having open revascularization, and at that point,
your limb salvage rate is still very similar to previously published
data for redo procedures. So I don’t know if it’s really that the
failure of the procedure leads to a problem or if it just indicates
more severe disease and they have to go on to another procedure,
like they might traditionally have to. Thanks for allowing me to
review this. I look forward to your responses.
Dr Omar Al-Nouri. Thank you, Dr Rossi. With regard to
your first question, when you break it down, if you take away the
claudication patients who were intervened on and you look at just
the critical limb ischemia, the limb salvage is pretty comparable to
open bypass. However, when SFA interventions fail, I think several
recent studies have shown that it might not have an absolute effect
on negative limb salvage, but it does change the distal target
bypass, and that might decrease the patency of the open revascu-
larization and make the bypass more difficult subsequently when
you do have a failed SFA intervention, which could lead to de-
creased limb salvage. When we looked at the numbers for our
patients, we used several CPT codes, and the 500 angioplasties that
we looked at, those were not only just balloon angioplasty/
stenting, but that included iliac interventions as well as diagnostic
angiograms. So it was a large amount of data to go through to find
just those 42 limbs. I think you’re right, we specifically looked at
patients that just underwent SFA stenting, we excluded patients
that underwent only balloon angioplasty, thus, we’re selecting out
for these more advanced lesions and maybe setting it up for
potentially having a failure. I’m sorry, the third and fourth ques-
tions? I apologize.
Dr Rossi.One was about medical management as far as using
statins or ACE inhibitors, and the other was about the assumption
that the failed percutaneous intervention leads to more difficult
procedures for limb salvage.
Dr Al-Nouri. For the medical management, we have always
put those patients on 30 days of Plavix postoperatively. We are
pretty involved in the statin therapy with the medical doctors as
well, so we do place the patients on statins if they were not on
statins before and they have an indication to be on statin therapy.
We talked about excellent vessel runoff, good vessel runoff, or poor
vessel runoff, with a score of 3, 2, and 1, respectively, but did not
break the patients down into these categories to see if they have a
better patency rate the higher the runoff score is. We are still
accruing data from the Veteran Affairs; once we have a more
substantial number of patients, we will definitely look at patency
rates broken down by runoff score.
s
t
patients considered high medical risk who would have previ-
ously been precluded from more traditional open bypass proce-
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iDrKarl Illig (Rochester, NY). I have good news and bad news
or you. The good news is that your article was very well presented
nd your data were very clear, and I thank you very much for that.
he bad news is that I have to pile on a little bit with regard to the
rior discussant’s fourth question. I don’t think you have really
nswered what you have set out to ask. Rather, you’ve really sort of
ust reaffirmed the definitions of TASC C and D lesions. In other
ords, your results really are nomore than the definitions of TASC
and D. The question you’re trying to answer is if you initially
pproach a patient using endovascular techniques, do you burn
our bridges; are youmaking things worse? A way of answering this
ould be to take your stented patients and blindly determine what
surgical bypass would have entailed, and then, when those who
ail do so, compare what they end up requiring. If a patient would
ave required bypass to the popliteal level originally and then after
failed stent requires a pedal bypass, you’ve burned your bridges.
e careful about saying that just because some patients went on to
mputation that you’re doing anything good or bad – that is the
atural history of this disease, and you cannot say that you have
hanged anything without some sort of control group.
Dr Al-Nouri. No, it’s a very good question. We are also
ooking at our open bypass experience within the same time period.
he idea when we set out looking at our SFA experience was how
an we tie this in exactly with a failed SFA intervention? Does it
urn our bridge in terms of the distal target that they might have?
o it’s one thing we are going to look at, as well as compare and
ook at the open bypass surgery and see, in this patient who failed
nd subsequently went on to have an open bypass, if it was the
atency rate as opposed to someone who did not fail initially and
ee if those are comparable or not.
Dr Illig. Because your number is so small, for this article you
ould really very easily figure out what their bypass would have
een and then what their bypass ended up being afterward.
Dr Al-Nouri. Yes.
Dr Philip Goodney (Lebanon, NH). That was nicely pre-
ented. I just wondered if you had calculated amputation-free
urvival curves or major adverse limb event curves. They would
elp to put into context some of the discussions that you’ve had
ith those who have come up to talk about your article. Patency is
ependent upon how long a patient lives, of course, and you put a
ot of stents into some very sick patients, and that might affect the
verall limb salvage rate, just because a patient might not live long
nough to get their amputation. Similarly, limb-specific outcome
easures, such as the major adverse limb events, which is one of
he Society for Vascular Surgery objective performance goals that
e’ll use to compare these results to open surgery, might effec-
ively contribute to your study. I wonder if you have that informa-
ion, and if you don’t, will you put it in your manuscript?
Dr Al-Nouri. I don’t have that information on hand right
ow. We’re still looking at it. But we are looking at the amputation-
ree survival and it probably will be in the manuscript. You know,
ooking at amputation-free survival, that number might not be as
ignificant as patency, and that’s kind of why we wanted to specif-
cally look at patency, because we did have a significant percentage
f patients (36%) who were claudicants. Those patients should
urvive. So, amputation-free survival might not be the best indica-
or in patients with critical limb ischemia.INVITED COMMENTARYRuth L. Bush, MD, MPH, Temple, Tex
The utilization of lower extremity endovascular interven-
tions for the treatment of both claudication and critical limb
ischemia has dramatically increased in the last decade. Part of
this increase may be accounted for because of technological
advances and part may be due to more aggressive treatment ofures. Dr Al-Nouri and colleagues have provided a detailed
nalysis of their institutional experience with endovascular in-
erventions in the superficial femoral artery. Despite the small
ize of the study group and the cohort heterogeneity, their
esults have produced some important treatment options and
ssential patient messages that can be used by the peripheral
nterventionalist.
